GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Other Current Payables

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Other Current Payables : $0.00 Mil (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Other Current Payables?

CERo Therapeutics Holdings's Other Current Payables for the quarter that ended in Dec. 2022 was $0.00 Mil.


CERo Therapeutics Holdings Other Current Payables Historical Data

The historical data trend for CERo Therapeutics Holdings's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Other Current Payables Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Other Current Payables
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Other Current Payables - -

CERo Therapeutics Holdings Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


CERo Therapeutics Holdings Other Current Payables Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines